These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 15927899)
1. Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus. Eurich DT; Simpson SH; Majumdar SR; Johnson JA Pharmacotherapy; 2005 Jun; 25(6):810-6. PubMed ID: 15927899 [TBL] [Abstract][Full Text] [Related]
2. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Johnson JA; Majumdar SR; Simpson SH; Toth EL Diabetes Care; 2002 Dec; 25(12):2244-8. PubMed ID: 12453968 [TBL] [Abstract][Full Text] [Related]
3. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Bowker SL; Majumdar SR; Veugelers P; Johnson JA Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869 [TBL] [Abstract][Full Text] [Related]
4. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Eurich DT; Majumdar SR; McAlister FA; Tsuyuki RT; Johnson JA Diabetes Care; 2005 Oct; 28(10):2345-51. PubMed ID: 16186261 [TBL] [Abstract][Full Text] [Related]
5. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Riedel AA; Heien H; Wogen J; Plauschinat CA Pharmacotherapy; 2007 Aug; 27(8):1102-10. PubMed ID: 17655510 [TBL] [Abstract][Full Text] [Related]
6. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes. Johnson JA; Simpson SH; Toth EL; Majumdar SR Diabet Med; 2005 Apr; 22(4):497-502. PubMed ID: 15787679 [TBL] [Abstract][Full Text] [Related]
7. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study. Mamza J; Mehta R; Donnelly R; Idris I Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210 [TBL] [Abstract][Full Text] [Related]
8. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. Currie CJ; Poole CD; Evans M; Peters JR; Morgan CL J Clin Endocrinol Metab; 2013 Feb; 98(2):668-77. PubMed ID: 23372169 [TBL] [Abstract][Full Text] [Related]
9. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Bowker SL; Yasui Y; Veugelers P; Johnson JA Diabetologia; 2010 Aug; 53(8):1631-7. PubMed ID: 20407744 [TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Second-Line Agents for the Treatment of Diabetes Type 2 in Preventing Kidney Function Decline. Hung AM; Roumie CL; Greevy RA; Grijalva CG; Liu X; Murff HJ; Ikizler TA; Griffin MR Clin J Am Soc Nephrol; 2016 Dec; 11(12):2177-2185. PubMed ID: 27827311 [TBL] [Abstract][Full Text] [Related]
11. Hypoglycemia Incidence Rates and Associated Health Care Costs in Patients with Type 2 Diabetes Mellitus Treated with Second-Line Linagliptin or Sulfonylurea After Metformin Monotherapy. Raju A; Shetty S; Cai B; D'Souza AO J Manag Care Spec Pharm; 2016 May; 22(5):483-92. PubMed ID: 27123911 [TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes. Min JY; Griffin MR; Hung AM; Grijalva CG; Greevy RA; Liu X; Elasy T; Roumie CL J Gen Intern Med; 2016 Jun; 31(6):638-46. PubMed ID: 26921160 [TBL] [Abstract][Full Text] [Related]
13. Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database. Rascati K; Richards K; Lopez D; Cheng LI; Wilson J Diabetes Obes Metab; 2013 Oct; 15(10):901-5. PubMed ID: 23531154 [TBL] [Abstract][Full Text] [Related]
14. The Risk of TB in Patients With Type 2 Diabetes Initiating Metformin vs Sulfonylurea Treatment. Pan SW; Yen YF; Kou YR; Chuang PH; Su VY; Feng JY; Chan YJ; Su WJ Chest; 2018 Jun; 153(6):1347-1357. PubMed ID: 29253553 [TBL] [Abstract][Full Text] [Related]
15. Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia. Yu O; Azoulay L; Yin H; Filion KB; Suissa S Am J Med; 2018 Mar; 131(3):317.e11-317.e22. PubMed ID: 29032229 [TBL] [Abstract][Full Text] [Related]
16. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study. Azoulay L; Schneider-Lindner V; Dell'aniello S; Schiffrin A; Suissa S Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):335-42. PubMed ID: 20052677 [TBL] [Abstract][Full Text] [Related]
17. Predictors of insulin initiation in metformin and sulfonylurea users in primary care practices: the role of kidney function. Kostev K; Dippel FW; Rathmann W J Diabetes Sci Technol; 2014 Sep; 8(5):1023-8. PubMed ID: 24876433 [TBL] [Abstract][Full Text] [Related]